SummaryRMgm-1100
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 25032958 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA GFP-con clone 2.3.4 |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Oppenheim, RD; Soldati-Favre, D |
Name Group/Department | Department of Microbiology and Molecular Medicine, Faculty of Medicine |
Name Institute | University of Geneva |
City | Geneva |
Country | Switzerland |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-1100 |
Principal name | Pbe1a_ko |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Strongly reduced growth of asexual blood stages. Evidence is presented that parasites can only develop into mature schizonts in reticulocytes and not in normocytes |
Gametocyte/Gamete | Lower production of male and female gametocytes. Reduced exflagellation of male gametocytes. |
Fertilization and ookinete | Lower production of male and female gametocytes. Reduced exflagellation of male gametocytes. Reduced ookinete production |
Oocyst | Reduced ookinete production Reduced oocyst production Aberrant formation of oocysts: reduced size and absence of sporogony (sporozoite formation) |
Sporozoite | Reduced ookinete production Reduced oocyst production Aberrant formation of oocysts: reduced size and absence of sporogony (sporozoite formation) Absence of salivary gland sporozoites |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1411100 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1312600 | ||||||||||||||||||||||||
Gene product | 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial, putative | ||||||||||||||||||||||||
Gene product: Alternative name | BCKDHA; BCKDH-E1a | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |